MINNEAPOLIS, Nov. 20, 2017 /PRNewswire/ — Bio-Techne updated its Flow Cytometry Panel Builder tool in July 2017 to support the use of its vast selection of over 18,000 conjugated antibodies, across targets and colors. The Flow Cytometry Panel Builder, a version of the FluoroFinder tool, was first launched in 2014 when this tool first became available to the scientific community. FluoroFinder® is a software company (a Software as a Service or SaaS) that specializes in experimental design and reagent search tools for flow cytometry and more recently, microscopy.
The updated FluoroFinder tool, available at NovusBio.com via the Flow Cytometry Panel Builder tool, has better performance and offers new features including Spectra Viewer (custom analysis of spectra from multiple fluorochromes) and Spillover Popups (visualize the spectra of individual fluorochromes). Overall, investigators have access to a tool that more efficiently streamlines the process of designing multicolor flow cytometry panels with Bio-Techne products and ensures compatibility with available cytometers in over 500 core facilities. Additionally, to facilitate the use of this tool by investigators, Bio-Techne released the Novus Panel Builder video tutorial, a step by step guide to automate multicolor panel design, accessible via the Novus website and YouTube.com.
FluoroFinder was first envisioned and founded by Roland Marcus. This cloud-based service was developed to simplify the design of complex cytometry panels. By automating the selection of cellular markers and fluorochrome-conjugated antibodies, researchers can reliably choose reagents for multi-channel cytometry experiments, avoiding errors from improper selection of reagents with significant spectral overlap.
“Thank you for providing an absolutely stellar service! In my book, FluoroFinder is the undisputed champion of online panel design and my most treasured tool for locating the antibodies that are actually available. Your attention to ‘simple’, yet very useful details of the user interface (such as the pop-up spectra and on-the-fly spillover estimates) is appreciated.” Mikkel Steen Petersen, PhD MSc – Clinical Flow Cytometrist, Aarhus University Hospital.
For the development of FluoroFinder Roland Marcus collaborated with Flow Cytometry Core facilities in different academic institutions and with providers of cytometry products. By integrating the specifications of cytometers available in multiple core facilities with the information on available reagents from suppliers, FluoroFinder became a one-stop shop for the design of cytometry experiments.
Two key benefits of automating the process of cytometer panel design are saving time and eliminating errors. Therefore, the new Novus Panel Builder provides investigators the benefit of more efficient experimentation and decreased research cost. Increased product visibility is a clear advantage for Bio-Techne, as the Flow Cytometry Panel Builder offers researchers a clear view into experimental design to efficiently and successfully utilize R&D Systems® and Novus Biologicals® reagents.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD’s in situ hybridization detection products — which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
David Clair, Investor Relations
SOURCE Bio-Techne Corporation